Anthracyclines News and Research

RSS

Pacemaker-like device improves heart function in patients with chemotherapy-induced cardiomyopathy

With the advent of new therapies, cancer patients are surviving longer than ever before -- but the incidence of side-effect chemotherapy-induced cardiomyopathy (CHIC), or weakness of the heart muscle, is increasing.

13 Nov 2019

Cardiac resynchronization therapy improves heart function in cancer survivors

A pacemaker-like device restored heart function in a group of cancer survivors -- mostly women with breast cancer -- who had suffered from heart failure as a result of chemotherapy treatment, a study in the Journal of the American Medical Association reports.

12 Nov 2019

Childhood cancer survivors have higher risk of developing heart disease

Survivors of childhood cancer have a higher risk of developing a range of heart disease due to cancer therapy, according to new research published in the American Heart Association's journal Circulation.

26 Aug 2019

Key metabolic changes found in patients with chemotherapy-related heart toxicity

More and more patients are being treated successfully for cancer. However, some cancer treatments that are very effective for breast cancer – medications like anthracyclines and trastuzumab – can cause heart dysfunction and lead to heart failure.

19 Jul 2019

Chemotherapy can wreak havoc on the heart

Cheryl Krafft was diagnosed with an aggressive form of non-Hodgkin's lymphoma and was put on a very high-powered chemotherapy regimen to rid her body of the cancer. What she was not counting on was the chemotherapy causing another equally deadly problem.

21 Jun 2019

Genetics may play a role in developing cancer therapy-induced cardiomyopathy

Recent advances in the development of cancer therapies have increased long-term survival and prognosis.

10 Apr 2019

Early marker of cardiac damage triggered by cancer treatment identified

Every year, 4 million new cases of cancer are diagnosed in Europe. Advances in cancer treatment sometimes come at the cost of major adverse effects, and one of the most prominent is cardiotoxicity. Myocardial toxicity affects as many as 25% of patients undergoing treatment with commonly used anticancer drugs.

19 Feb 2019

New study compares chemotherapy drugs with development of cardiomyopathy

In long-term survivors of childhood cancer, cardiovascular disease is a leading cause of early death from non-cancer causes.

1 Feb 2019

New discovery could pave way for improved leukemia treatment

Previous research has revealed that patients with acute myeloid leukemia who also have a particular mutation in a gene called NPM1 have a higher rate of remission with chemotherapy. About one-third of leukemia patients possess this favorable mutation, but until now, how it helps improve outcomes has remained unknown.

9 Aug 2018

Combating cardiac complications caused by cancer treatment

Amie Goins has completed eight 5K runs in 2018. An impressive feat for a 46-year-old mother with a full-time job and two teenage sons to care for – downright astounding for a woman who was diagnosed with stage 2 breast cancer two days before Christmas last year. She's conquered months of treatment and difficult side effects while continuing to lace up.

26 Jun 2018

Study tests accuracy of device designed to detect heart dysfunction in childhood cancer survivors

A wireless device designed for detection of heart dysfunction in childhood cancer survivors treated with anthracycline chemotherapy was accurate and displayed a low false-negative rate as compared to cardiac magnetic resonance imaging.

21 Jun 2018

Breast cancer patients may be at increased risk of cardiovascular diseases

Breast cancer patients may be at an increased risk of cardiovascular diseases including heart failure and may benefit from a treatment approach that weighs the benefits of specific therapies against potential damage to the heart, according to a new scientific statement from the American Heart Association published in its journal Circulation.

1 Feb 2018

Adults that survived childhood cancer are at risk of developing hypertension, study reveals

A new study, published in Cancer Epidemiology, Biomarkers & Prevention, indicates that adult survivors of childhood cancer were found to have a twofold increased risk of hypertension (high blood pressure) as adults, when compared with the general population.

24 Nov 2017

Childhood cancer survivors more likely to have high blood pressure as adults

People who survived childhood cancer were more than twice as likely as the general population to have high blood pressure (hypertension) as adults.

22 Nov 2017

Adipocytes may reduce effectiveness of chemotherapeutic drug

Adipocytes, or fat cells, can absorb and metabolize the chemotherapeutic agent daunorubicin, reducing the effectiveness of the drug and potentially contributing to poorer treatment outcomes.

8 Nov 2017

Nebivolol treatment may protect against antracycline-induced cardiotoxicity in breast cancer patients

Nebivolol prevents anthracycline-induced cardiotoxicity, according to research presented at ESC Congress 2016 today by Professor Mirela Cleopatra Tomescu, a cardiologist at Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.

30 Aug 2016

ESC releases novel position paper on tackling cardiotoxicity of anticancer treatments

The European Society of Cardiology has launched a novel position paper, under the auspices of its Committee for Practice Guidelines, on tackling the cardiac toxicity of anticancer therapies. The cardio-oncology paper is published online today in European Heart Journal and on the ESC Website.

27 Aug 2016

Women undergoing breast cancer treatment are not getting recommended follow-up heart scans

Despite the known toxic effects of chemotherapy on the heart, the majority of women undergoing breast cancer treatment are not getting the recommended follow-up heart scans, according to research presented at the British Cardiovascular Society Conference in Manchester today.

6 Jun 2016

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab.

23 May 2016

AKR1C3 enzyme could be promising therapeutic target for managing CRPC, AML

Prostate cancer is the second leading cause of mortality among American men with the highest incidence rate of all cancers reported in the U.S. Male sex hormones testosterone (T) and 5α-dihydrotestosterone (5α-DHT) promote prostate cancer progression.

19 May 2016